Developers take another shot at an Alzheimer's vaccine
But the current leader, Vaxxinity, will have to convince its doubters if it is to hook a partner.
GSK’s tribulations continue
Two days ago GSK canned lete-cel. Now it is ditching otilimab, and daprodustat’s future is looking dicey.
